PolyPid to Present Phase 3 Trial Data on Surgical Site Infection Reduction at 2026 Meeting
PolyPid Ltd., a biopharmaceutical company, is set to present findings from its Phase 3 SHIELD II trial at the 45th Annual Meeting of the Surgical Infection Society in Coronado, California. The trial focused on D-PLEX 100, a product designed to prevent surgical site infections (SSIs) by providing prolonged and controlled antibacterial activity directly at the surgical site. The trial demonstrated a 60% reduction in the severity of SSIs, as measured by the ASEPSIS score, which assesses wound infection severity. The presentation will be delivered by Dr. Robert G. Sawyer, a professor at Western Michigan University, highlighting the potential of D-PLEX 100 to improve patient outcomes and reduce hospital resource utilization. 
